CD274 and head and neck squamous cell carcinoma: However, PD-L1 therapeutic validation set applied in this research was urothelium carcinoma rather than HNSCC and TIDE score focus on CTL rather than the whole immune TME, so the predicting effect was limited since other potential molecules was not taken into consideration.